ABIOMED, Inc. (NASDAQ:ABMD) Shares Purchased by First Trust Advisors LP

First Trust Advisors LP lifted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 36.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,776 shares of the medical equipment provider’s stock after acquiring an additional 747 shares during the period. First Trust Advisors LP’s holdings in ABIOMED were worth $494,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of ABMD. Executive Wealth Management LLC raised its holdings in shares of ABIOMED by 100.0% during the second quarter. Executive Wealth Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 50 shares during the period. CIBC Asset Management Inc increased its stake in ABIOMED by 2.1% in the 2nd quarter. CIBC Asset Management Inc now owns 4,093 shares of the medical equipment provider’s stock valued at $1,066,000 after buying an additional 85 shares during the period. Tyers Asset Management LLC increased its stake in ABIOMED by 5.8% in the 2nd quarter. Tyers Asset Management LLC now owns 1,760 shares of the medical equipment provider’s stock valued at $458,000 after buying an additional 96 shares during the period. Caisse DE Depot ET Placement DU Quebec increased its stake in ABIOMED by 11.1% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,000 shares of the medical equipment provider’s stock valued at $260,000 after buying an additional 100 shares during the period. Finally, Moors & Cabot Inc. increased its stake in ABIOMED by 5.8% in the 3rd quarter. Moors & Cabot Inc. now owns 1,825 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 100 shares during the period. 90.68% of the stock is owned by institutional investors.

ABMD stock opened at $193.89 on Thursday. The company has a market capitalization of $8.86 billion, a price-to-earnings ratio of 53.86, a P/E/G ratio of 1.72 and a beta of 0.32. ABIOMED, Inc. has a 12 month low of $155.02 and a 12 month high of $364.31. The firm has a 50 day moving average of $196.29 and a two-hundred day moving average of $217.75.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, October 31st. The medical equipment provider reported $1.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.93 by $0.10. The company had revenue of $204.97 million during the quarter, compared to the consensus estimate of $206.45 million. ABIOMED had a net margin of 26.92% and a return on equity of 19.89%. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 earnings per share. As a group, sell-side analysts expect that ABIOMED, Inc. will post 4.32 earnings per share for the current fiscal year.

Several research firms have weighed in on ABMD. ValuEngine upgraded shares of ABIOMED from a “sell” rating to a “hold” rating in a research note on Wednesday, September 4th. Raymond James downgraded shares of ABIOMED from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 29th. Leerink Swann boosted their target price on shares of ABIOMED from $195.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. TheStreet downgraded shares of ABIOMED from a “b-” rating to a “c+” rating in a research report on Thursday, August 22nd. Finally, William Blair reissued a “buy” rating on shares of ABIOMED in a research report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $301.20.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: Initial Coin Offering (ICO)

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.